Clinical trials: Endocrine System Disorder
Type 1 Diabetes Mellitus
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
- Trial name
- NCT06152042
- Testing
- BMF-219
- Where
- 11 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Biomea Fusion Inc.
Pancreatic Neoplasms
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer
A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.
- Trial name
- NCT00191568
- Testing
- Gemcitabine, Oxaliplatin, Radiotherapy
- Where
- 6 sites in France
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
- Trial name
- NCT00976391
- Testing
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Where
- 209 sites in United States, Brazil and 12 more
- Volunteers
- 586 people
- Sponsor
- GlaxoSmithKline
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem, Small for Gestational Age
- Trial name
- NCT01245374
- Testing
- Norditropin NordiFlex®
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Secondary Hypogonadism
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
The purpose of this study is to determine the effect the investigative drug has on glycemic control in men with type 2 diabetes mellitus (T2DM) and secondary hypogonadism
- Trial name
- NCT01191320
- Testing
- Androxal
- Where
- 18 sites in United States
- Volunteers
- 102 people
- Sponsor
- Repros Therapeutics Inc.
Diabetes Mellitus, Type 2
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.
- Trial name
- NCT00631488
- Testing
- MK-0893, Sitagliptin, Metformin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Dose Ranging Study of Albiglutide in Japanese Subjects
This is a randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging study evaluating the dose response, efficacy and safety of subcutaneously injected GSK716155 (albiglutide) in Japanese subjects…
- Trial name
- NCT01098461
- Testing
- albiglutide
- Where
- 30 sites in Japan
- Volunteers
- 215 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects.
- Trial name
- NCT02151461
- Testing
- Low Metformin, Metformin, Mid Metformin
- Where
- 9 sites in United States
- Volunteers
- 96 people
- Sponsor
- NuSirt Biopharma
Type 1 Diabetes Mellitus
Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)
The purpose of this study is to assess the long term safety and efficacy in subjects with Type 1 Diabetes Mellitus who completed the Protege Study (CP-MGA031-01).
- Trial name
- NCT00870818
- Testing
- Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- MacroGenics
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01843127
- Testing
- Ranolazine, Exenatide
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes
The study will evaluate the efficacy and tolerability of saxagliptin compared to uptitration of metformin in patients with type 2 diabetes who have inadequate glycaemic control on a submaximal dose of metformin.
- Trial name
- PROMPT (NCT01006590)
- Testing
- Saxagliptin, Metformin
- Where
- 51 sites in Belgium, France and 5 more
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Primary Ovarian Insufficiency, Vaginitis
A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.
The purpose of this study is to assess the bioequivalence and food effect for a new Premarin formulation compared with a Premarin reference tablet in Japanese healthy postmenopausal women.
- Conditions
- Primary Ovarian Insufficiency, Vaginitis, Metrorrhagia, Menopause
- Trial name
- NCT01436513
- Testing
- Premarin reference tablet (fasted), Premarin new tablet (fasted), Premarin reference tablet (fed)
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
The primary aim of this exploratory mechanistic study is to investigate the effects of Empagliflozin and Linagliptin on alpha- and beta cell physiology in T2DM patients.
- Trial name
- NCT02401880
- Testing
- Linagliptin, Empagliflozin
- Where
- 2 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2…
- Trial name
- NCT07275788
- Testing
- REGEND003
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Regend Therapeutics
Foot Ulcer, Diabetic Foot
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
The purpose of this study is to evaluate the efficacy and safety of REGRANEX® Gel compared with placebo when applied for up to 52 consecutive weeks to recurring or non-healing ulcers of the ankle or foot related to diabetes.
- Conditions
- Foot Ulcer, Diabetic Foot, Skin Ulcer, Diabetic Neuropathies
- Trial name
- NCT00034788
- Testing
- Becaplermin
- Volunteers
- 84 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Diabetes Mellitus Type 2
Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus
The purpose of this study is to explore the mode of action of topiramate in the treatment of obese and diabetic patients by testing association between genetic variations within candidate genes or chromosomes (thread like…
- Trial name
- NCT00304603
- Testing
- No intervention
- Volunteers
- 1,145 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Elevated Body Mass Index
Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index
A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)
- Trial name
- NCT02470403
- Testing
- LIK066
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03907527
- Testing
- PRGN-3005 UltraCAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Precigen, Inc
Ovarian Cancer
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors.
- Trial name
- BOUQUET (NCT04931342)
- Testing
- Ipatasertib, Cobimetinib, Trastuzumab Emtansine
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 176 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
- Trial name
- RECAP (NCT01423604)
- Testing
- Capecitabine, Ruxolitinib
- Where
- 39 sites in United States
- Volunteers
- 136 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.